Lexeo Details 30% LV Mass Reduction, FDA OKs Pooled Phase I/II for LX2006
Lexeo's LX2006 achieved up to 30% LV mass reduction and normalized LVMI for Friedreich’s ataxia cardiomyopathy, with FDA allowing Phase I/II pooling and shorter follow-up, pending a statistical plan update in early 2026. Its PKP2 program showed up to 65% NSVT reduction and ~30% ejection fraction gains with acceptable safety.
1. LX2006 Clinical Data and FDA Path
Lexeo’s lead program, LX2006, demonstrated up to 30% reduction in left ventricular mass and normalization of LVMI in Friedreich’s ataxia cardiomyopathy patients with abnormal baseline values. The FDA has agreed to pool Phase I/II patients with a registrational study and consider a follow-up shorter than 12 months, with a final statistical plan and study design due early 2026.
2. PKP2 Gene Therapy Progress
The arrhythmogenic cardiomyopathy program targeting PKP2 mutations showed a ~22% NSVT reduction versus ~20% worsening in natural history, up to 65% NSVT reduction in one patient, and ~30% ejection fraction improvement. The therapy has maintained a generally favorable safety profile, aside from one serious adverse event in a patient with prior sustained ventricular tachycardia.
3. Manufacturing and Pivotal Trial Planning
Lexeo completed a clinical batch using its final commercial Sf9 suspension process with FDA-approved comparability, enabling pivotal dosing. LX2006 is dosed at 1×10^12 vector genomes per kilogram with a low-dose prednisone regimen and expects to include adolescent and pediatric cohorts, while a process validation designation supports accelerated development.